Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome

Ann Oncol. 2015 May;26(5):880-887. doi: 10.1093/annonc/mdv127. Epub 2015 Mar 2.


Background: Glioblastoma (GBM) is the most common malignant brain cancer occurring in adults, and is associated with dismal outcome and few therapeutic options. GBM has been shown to predominantly disrupt three core pathways through somatic aberrations, rendering it ideal for precision medicine approaches.

Methods: We describe a 35-year-old female patient with recurrent GBM following surgical removal of the primary tumour, adjuvant treatment with temozolomide and a 3-year disease-free period. Rapid whole-genome sequencing (WGS) of three separate tumour regions at recurrence was carried out and interpreted relative to WGS of two regions of the primary tumour.

Results: We found extensive mutational and copy-number heterogeneity within the primary tumour. We identified a TP53 mutation and two focal amplifications involving PDGFRA, KIT and CDK4, on chromosomes 4 and 12. A clonal IDH1 R132H mutation in the primary, a known GBM driver event, was detectable at only very low frequency in the recurrent tumour. After sub-clonal diversification, evidence was found for a whole-genome doubling event and a translocation between the amplified regions of PDGFRA, KIT and CDK4, encoded within a double-minute chromosome also incorporating miR26a-2. The WGS analysis uncovered progressive evolution of the double-minute chromosome converging on the KIT/PDGFRA/PI3K/mTOR axis, superseding the IDH1 mutation in dominance in a mutually exclusive manner at recurrence, consequently the patient was treated with imatinib. Despite rapid sequencing and cancer genome-guided therapy against amplified oncogenes, the disease progressed, and the patient died shortly after.

Conclusion: This case sheds light on the dynamic evolution of a GBM tumour, defining the origins of the lethal sub-clone, the macro-evolutionary genomic events dominating the disease at recurrence and the loss of a clonal driver. Even in the era of rapid WGS analysis, cases such as this illustrate the significant hurdles for precision medicine success.

Keywords: double minute chromosome; glioblastoma; intra-tumour heterogeneity; multi-region sequencing.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Brain Neoplasms / enzymology
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • Chemotherapy, Adjuvant
  • Chromosomes, Human*
  • Cyclin-Dependent Kinase 4 / genetics
  • Dacarbazine / analogs & derivatives
  • Dacarbazine / therapeutic use
  • Disease Progression
  • Fatal Outcome
  • Female
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Glioblastoma / enzymology
  • Glioblastoma / genetics*
  • Glioblastoma / pathology
  • Glioblastoma / therapy
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Isocitrate Dehydrogenase / genetics*
  • Mutation*
  • Neoplasm Grading
  • Neoplasm Recurrence, Local
  • Neurosurgical Procedures
  • Phenotype
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-kit / genetics
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Temozolomide
  • Time Factors
  • Treatment Outcome


  • Antineoplastic Agents, Alkylating
  • Protein Kinase Inhibitors
  • Dacarbazine
  • Imatinib Mesylate
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • Proto-Oncogene Proteins c-kit
  • Receptor, Platelet-Derived Growth Factor alpha
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4
  • Temozolomide